These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33774685)

  • 1. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer.
    Seban RD; Rouzier R; Latouche A; Deleval N; Guinebretiere JM; Buvat I; Bidard FC; Champion L
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3560-3570. PubMed ID: 33774685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
    Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated splenic 18F-fluorodeoxyglucose positron emission tomography/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast.
    Wang Y; Li Y; Jiang H; Zuo C; Xu W
    Br J Radiol; 2024 Jan; 97(1153):237-248. PubMed ID: 38263821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
    Jin P; Bai M; Liu J; Yu J; Meng X
    Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
    Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
    Seban RD; Assié JB; Giroux-Leprieur E; Massiani MA; Bonardel G; Chouaid C; Deleval N; Richard C; Mezquita L; Girard N; Champion L
    Lung Cancer; 2021 Sep; 159():45-55. PubMed ID: 34311344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
    Seban RD; Arnaud E; Loirat D; Cabel L; Cottu P; Djerroudi L; Hescot S; Loap P; Bonneau C; Bidard FC; Huchet V; Jehanno N; Berenbaum A; Champion L; Buvat I
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4024-4035. PubMed ID: 37606858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardized uptake value of ¹⁸F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden.
    Ahn SG; Park JT; Lee HM; Lee HW; Jeon TJ; Han K; Lee SA; Dong SM; Ryu YH; Son EJ; Jeong J
    Breast Cancer Res; 2014; 16(6):502. PubMed ID: 25551703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer.
    Bang JI; Yoon HJ; Kim BS
    PLoS One; 2018; 13(12):e0208861. PubMed ID: 30532215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[
    Wu C; Cui Y; Liu J; Ma L; Xiong Y; Gong Y; Zhao Y; Zhang X; Chen S; He Q; Zhang J; Liu M; Fan Y
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4054-4066. PubMed ID: 33978830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Seban RD; Mezquita L; Berenbaum A; Dercle L; Botticella A; Le Pechoux C; Caramella C; Deutsch E; Grimaldi S; Adam J; Ammari S; Planchard D; Leboulleux S; Besse B
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1147-1157. PubMed ID: 31754795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Lee JW; Kim SY; Han SW; Lee JE; Lee HJ; Heo NH; Lee SM
    EJNMMI Res; 2020 Jun; 10(1):72. PubMed ID: 32607957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Pre-Therapeutic [18F]FDG PET/CT Imaging for Predicting Outcomes in Breast Cancer.
    Najid S; Seban RD; Champion L; De Moura A; Sebbag C; Salaün H; Cabel L; Bonneau C
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685551
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of FDG PET/CT imaging features with tumor immune microenvironment and prognosis in colorectal cancer: a retrospective study.
    Lee JW; Ahn H; Yoo ID; Hong SP; Baek MJ; Kang DH; Lee SM
    Cancer Imaging; 2024 Apr; 24(1):53. PubMed ID: 38627864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
    Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.